Drug Profile
Research programme: rheumatoid arthritis and psoriasis therapy - Devgen
Alternative Names: CDE 6960Latest Information Update: 09 Dec 2008
Price :
$50
*
At a glance
- Originator Devgen
- Class
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis; Rheumatoid arthritis
Most Recent Events
- 05 Nov 2008 Discontinued - Preclinical for Psoriasis in Belgium (PO)
- 05 Nov 2008 Discontinued - Preclinical for Rheumatoid arthritis in Belgium (PO)
- 11 Jul 2008 Preclinical trials in Psoriasis in Belgium (PO)